Literature DB >> 26068521

Metabolism of the anthelmintic drug niclosamide by cytochrome P450 enzymes and UDP-glucuronosyltransferases: metabolite elucidation and main contributions from CYP1A2 and UGT1A1.

Danyi Lu1, Zhiguo Ma1, Tianpeng Zhang1, Xingwang Zhang1, Baojian Wu1.   

Abstract

1. Niclosamide is an old anthelmintic drug that shows potential in fighting against cancers. Here, we characterized the metabolism of niclosamide by cytochrome P450 enzymes (CYPs) and UDP-glucuronosyltransferases (UGTs) using human liver microsomes (HLM) and expressed enzymes. 2. NADPH-supplemented HLM (and liver microsomes from various animal species) generated one hydroxylated metabolite (M1) from niclosamide; and UDPGA-supplemented liver microsomes generated one mono-O-glucuronide (M2). The chemical structures of M1 (3-hydroxy niclosamide) and M2 (niclosamide-2-O-glucuronide) were determined through LC-MS/MS and/or NMR analyses. 3. Reaction phenotyping revealed that CYP1A2 was the main enzyme responsible for M1 formation. The important role of CYP1A2 in niclosamide metabolism was further confirmed by activity correlation analyses as well as inhibition experiments using specific inhibitors. 4. Although seven UGT enzymes were able to catalyze glucuronidation of niclosamide, UGT1A1 and 1A3 were the enzymes showed the highest metabolic activities. Activity correlation analyses demonstrated that UGT1A1 played a predominant role in hepatic glucuronidation of niclosamide, whereas the role of UGT1A3 was negligible. 5. In conclusion, niclosamide was subjected to efficient metabolic reactions hydroxylation and glucuronidation, wherein CYP1A2 and UGT1A1 were the main contributing enzymes, respectively.

Entities:  

Keywords:  CYP; UGT; glucuronidation; hydroxylation; niclosamide; reaction phenotyping

Mesh:

Substances:

Year:  2015        PMID: 26068521     DOI: 10.3109/00498254.2015.1047812

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  7 in total

1.  Contributions of Hepatic and Intestinal Metabolism to the Disposition of Niclosamide, a Repurposed Drug with Poor Bioavailability.

Authors:  Xiaoyu Fan; Hongmin Li; Xinxin Ding; Qing-Yu Zhang
Journal:  Drug Metab Dispos       Date:  2019-04-30       Impact factor: 3.922

2.  Maternal-to-zygotic transition as a potential target for niclosamide during early embryogenesis.

Authors:  Sara M F Vliet; Subham Dasgupta; Nicole R L Sparks; Jay S Kirkwood; Alyssa Vollaro; Manhoi Hur; Nicole I Zur Nieden; David C Volz
Journal:  Toxicol Appl Pharmacol       Date:  2019-08-06       Impact factor: 4.219

3.  Niclosamide Induces Epiboly Delay During Early Zebrafish Embryogenesis.

Authors:  Sara M Vliet; Subham Dasgupta; David C Volz
Journal:  Toxicol Sci       Date:  2018-12-01       Impact factor: 4.849

4.  Systematic identification of biomarker-driven drug combinations to overcome resistance.

Authors:  Matthew G Rees; Lisa Brenan; Mariana do Carmo; Patrick Duggan; Besnik Bajrami; Michael Arciprete; Andrew Boghossian; Emma Vaimberg; Steven J Ferrara; Timothy A Lewis; Danny Rosenberg; Tenzin Sangpo; Jennifer A Roth; Virendar K Kaushik; Federica Piccioni; John G Doench; David E Root; Cory M Johannessen
Journal:  Nat Chem Biol       Date:  2022-03-24       Impact factor: 16.174

5.  In Vitro Glucuronidation of Wushanicaritin by Liver Microsomes, Intestine Microsomes and Expressed Human UDP-Glucuronosyltransferase Enzymes.

Authors:  Xiaodan Hong; Yuanru Zheng; Zifei Qin; Baojian Wu; Yi Dai; Hao Gao; Zhihong Yao; Frank J Gonzalez; Xinsheng Yao
Journal:  Int J Mol Sci       Date:  2017-09-19       Impact factor: 5.923

6.  Metabolite Profiling, Pharmacokinetics, and In Vitro Glucuronidation of Icaritin in Rats by Ultra-Performance Liquid Chromatography Coupled with Mass Spectrometry.

Authors:  Beibei Zhang; Xiaoli Chen; Rui Zhang; Fangfang Zheng; Shuzhang Du; Xiaojian Zhang
Journal:  J Anal Methods Chem       Date:  2017-07-10       Impact factor: 2.193

Review 7.  Techniques for analytical estimation of COVID-19 clinical candidate, niclosamide in pharmaceutical and biomedical samples.

Authors:  Deepank S Gupta; Sonali S Bharate
Journal:  Sep Sci Plus       Date:  2022-09-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.